Johnson & Johnson: U.S. FDA Oncologic Drugs Advisory Committee recommends CARVYKTI (ciltacabtagene autoleucel) for the earlier treatment of patients with relapsed or refractory multiple myeloma

Media coverage

• Title	Johnson & Johnson: U.S. FDA Oncologic Drugs Advisory Committee recommends CARVYKTI (ciltacabtagene autoleucel) for the earlier treatment of patients with relapsed or refractory multiple myeloma
  Media name/outlet	India Pharma News
  Country/Territory	India
  Date	15/03/24
  Persons	Sundar Jagannath